Glenn Hanna, MD, and Nabil F. Saba, MD, FACP, discuss recent data on use of tipifarnib in HRAS-mutant head and neck squamous cell carcinoma.
EP. 1: The Evolving Treatment Landscape of HNSCC
A brief overview of treatment advances for HRAS-mutated head and neck squamous cell carcinoma.
EP. 2: Molecular Testing in HNSCC
Guidance for incorporating initial and repeat molecular testing in head and neck cancers into clinical practice.
EP. 3: Tipifarnib in HRAS-Mutated HNSCC
Potential implications for treating patients with HRAS-mutated head and neck cancer with tipifarnib, based on results demonstrated by the RUN-HN study.
EP. 4: Pivotal AIM-HN Clinical Trial of Tipifarnib in HNSCC
Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, discuss the design and potential clinical implications of the AIM-HN trial of tipifarnib in head and neck cancers.
EP. 5: Future Directions in HRAS-Mutated Head and Neck Cancer
Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, highlight potential new therapies for head and neck squamous cell carcinoma in various patient populations.
EP. 6: Managing Adverse Events With Tipifarnib
Recommendations for mitigating and managing treatment-related adverse events associated with tipifarnib.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer